Eva K. Kempers

Eva K. Kempers

Auto-generated profile, based on publicly available information

Eva K. Kempers

Department of Hematology, Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
FAFerdows Atiq
Ferdows Atiq
JHJessica Maria Heijdra
Jessica Maria Heijdra
FSFleur Snijders
Fleur Snijders
JBJohan Boender
Johan Boender
EKEva Kempers
Eva Kempers
FLFrank W. G. Leebeek
Frank W. G. Leebeek
Patients with type 1 and type 2 von Willebrand disease (VWD) can be treated with desmopressin. Although a previous study has shown that the location of the causative VWF gene variant is associated with desmopressin response in type 1 VWD, the association between variants in the VWF gene and desmopressin response is not yet fully understood. Our primary aim was to compare desmopressin response in type 1 VWD patients with and without a VWF gene variant. Secondly, we investigated whether desmopressin response depends on specific VWF gene variants in type 1 and type 2 VWD. We included 250 patients from the Willebrand in the Netherlands study: 72 type 1 without a VWF gene variant, 108 type 1 with a variant, 45 type 2A, 16 type 2M, and 9 type 2N patients. VWF gene was analyzed with ion semiconductor sequencing and Multiplex Ligation-dependent Probe Amplification. Complete response to desmopressin was observed in all type 1 VWD patients without a variant, 64.3% of type 1 patients with a variant, and 31.3% of type 2 patients (P < .001). Despite a large interindividual variability in desmopressin response, patients with the same variant had comparable desmopressin responses. For instance, in 6 type 1 patients with exon 4 to 5 deletion, mean VWF activity at 1 hour after desmopressin was 0.81 IU/mL, with a coefficient of variation of 22.9%. In conclusion, all type 1 VWD patients without a VWF gene variant respond to desmopressin. In type 1 and type 2 VWD patients with a VWF variant, desmopressin response highly depends on the VWF gene variants.

2 April 2025 in European Heart Journal
Verified
Journal Article
Open access
QCQingui Chen
Qingui Chen
NRNienke van Rein
Nienke van Rein
LSLuuk J J Scheres
Luuk J J Scheres
EKEva K Kempers
Eva K Kempers
CVChantal Visser
Chantal Visser
SCSuzanne C Cannegieter
Suzanne C Cannegieter
Background and Aims: Epidemiology of pulmonary embolism (PE) may have shifted since the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to describe temporal trends in PE epidemiology in the Netherlands since 2015. Methods: Using nationwide data from Statistics Netherlands, all Dutch inhabitants (>16 million) without a history of PE were dynamically identified on 1 January of each year to assemble eight cohorts of PE-free Dutch inhabitants in 2015–22. They were individually followed until the end of that respective year to determine 1-year risk of PE (identified by hospital diagnoses/primary cause of death) and establish relevant risk factors. The PE cases were subsequently studied to determine 1-year all-cause mortality following PE. Multivariable logistic regression with cluster-robust standard errors and robust Poisson regression were respectively employed to evaluate relative differences in PE incidence and mortality between years. Results: Pulmonary embolism incidence in the Dutch population decreased from 2015 to 2019 but markedly increased by 23% (95% confidence interval 20%–26%), 52% (48%–56%), and 7% (4%–9%) in 2020–22 (vs. 2019), respectively. Most traditional PE risk factors remained associated with PE in 2020–22 but generally with a weaker association. Pulmonary embolism mortality was stable until 2019 but then increased by 10% (6%–14%) in 2020 and 9% (6%–13%) in 2021, while the increase [2% (−1% to 6%)] was insignificant in 2022. The above-mentioned changes since 2020 were generally greater in males than females. Conclusions: The seemingly favourable pre-pandemic temporal trends in PE epidemiology in the Netherlands reversed during the COVID-19 pandemic but appear to revert to pre-pandemic levels after 2022.

24 January 2025 in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
EKEva K. Kempers
Eva K. Kempers
CVChantal Visser
Chantal Visser
EGEric C. T. Geijteman
Eric C. T. Geijteman
JGJamilla Goedegebuur
Jamilla Goedegebuur
JPJohanneke E. A. Portielje
Johanneke E. A. Portielje
MKMarieke Kruip
Marieke Kruip
Data on risks and benefits of long-term anticoagulants in patients with a life-limiting disease are limited. This cohort study aims to describe (dis)continuation of anticoagulants and incidences of bleeding and thromboembolic events in vitamin K antagonist (VKA) users with a life-limiting disease. Data from five Dutch anticoagulation clinics were linked to data from Statistics Netherlands and the Netherlands Cancer registry. Prevalent VKA users diagnosed with a pre-specified life-limiting disease between January 1, 2013 and December 31, 2019 were included and followed until December 31, 2019. Bleeding and thromboembolic events were identified by hospitalization data. Cumulative incidences of anticoagulant discontinuation, accounting for death as competing risk, and event rates for both anticoagulant exposed and unexposed person-years (PYs) were determined. Among 18,145 VKA users (median age 81 years [IQR: 74–86], 49% females, median survival time 2.03 years [95%CI: 1.97–2.10]), the most common life-limiting diseases were heart disease (60.0%), hip fracture (18.1%), and cancer (13.5%). One year after diagnosis, the cumulative incidence of anticoagulant discontinuation was 14.0% (95%CI: 13.5–14.6). Over 80% of patients continued anticoagulant therapy until the last month before death, with median 14 days between discontinuation and death. Event rates per 100 PYs (95%CI) were comparable during anticoagulant use and after discontinuation for bleeding 2.6 (2.4–2.8) versus 2.1 (1.5–2.8), venous thromboembolism 0.2 (0.1–0.2) versus 0.4 (0.2–0.7), and arterial thromboembolism 3.1 (2.9–3.3) versus 3.3 (2.6–4.2). Most VKA users with a life-limiting disease continued anticoagulant treatment during their last phase of life, with similar rates of bleeding and thromboembolic events during use and after discontinuation.

1 September 2025 in British Journal of Haematology
Verified
Journal Article
Open access
SASarah J. Aldridge
Sarah J. Aldridge
AAAshley Akbari
Ashley Akbari
AEAdrian Edwards
Adrian Edwards
KLKate J. Lifford
Kate J. Lifford
DADenise Abbel
Denise Abbel
SNSimon Noble
Simon Noble
Summary: Anti‐thrombotic therapy (ATT) in cancer patients approaching the end of life presents significant clinical challenges, balancing thrombotic and bleeding risks. This study analysed ATT prescribing patterns and associated outcomes in patients diagnosed with poor prognosis cancer, defined as cancer diagnoses associated with a 1‐year life expectancy, using the Welsh national Secure Anonymised Information Linkage Databank. Retrospective cohort study of adults in Wales diagnosed with poor prognosis cancer between 2013 and 2021, following up patients from cancer diagnosis until death, end of follow‐up or study end (31 December 2021). Outcomes included ATT discontinuation, bleeding and thromboembolic events in secondary care. We identified a cohort of 25 783 adults with a median survival of 145 days. Of these, 32% were receiving ATT at diagnosis, with 77% continuing until death. One‐year cumulative incidence of ATT discontinuation was 19% (95% CI: 18%–20%). The 1‐year cumulative incidence of bleeding was 3.2% (95% CI: 3.0%–3.4%) and of thromboembolic events was 5.3% (95% CI: 5.0%–5.6%). ATT was prevalent at cancer diagnosis and discontinuation before death was uncommon. The management of ATT is complex in patients with advanced cancer and there is a need for clearer guidance on appropriate discontinuation strategies as well as when to continue these medicines.

8 August 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EKEva K. Kempers
Eva K. Kempers
QCQingui Chen
Qingui Chen
CVChantal Visser
Chantal Visser
EGEric C.M. van Gorp
Eric C.M. van Gorp
FKFrederikus A. Klok
Frederikus A. Klok
MKMarieke Kruip
Marieke Kruip
This population-based cohort study aimed to describe changes in incidence of cardiovascular disease (CVD) hospital diagnoses during the COVID-19 pandemic in The Netherlands compared with the pre-pandemic period. We used Dutch nationwide statistics about hospitalizations to estimate incidence rate ratios (IRR) of hospital diagnoses of CVD during the first and second COVID-19 waves in The Netherlands in 2020 versus the same periods in 2019. Compared with 2019, the incidence rate of a hospital diagnosis of ischemic stroke (IRR 0.87; 95% CI 0.79–0.95), major bleeding (IRR 0.74; 95% CI 0.68–0.82), atrial fibrillation (IRR 0.73; 95% CI 0.65–0.82), myocardial infarction (IRR 0.78; 95% CI 0.72–0.84), and heart failure (IRR 0.74; 95% CI 0.65–0.85) declined during the first wave, but returned to pre-pandemic levels throughout 2020. However, the incidence rate of a hospital diagnosis of pulmonary embolism (PE) increased during both the first and second wave in 2020 compared with 2019 (IRR 1.30; 95% CI 1.15–1.48 and IRR 1.31; 95% CI 1.19–1.44, respectively). In conclusion, we observed substantial declines in incidences of CVD during the COVID-19 pandemic in The Netherlands in 2020, especially during the first wave, with an exception for an increase in incidence of PE. This study contributes to quantifying the collateral damage of the COVID-19 pandemic.

27 November 2021 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
PDF file
EKEva K Kempers
Eva K Kempers
VDVirgil A S H Dalm
Virgil A S H Dalm
MRMarie Josee E van Rijn
Marie Josee E van Rijn
AMAnnemarie G M G J Mulders
Annemarie G M G J Mulders
FLFrank W G Leebeek
Frank W G Leebeek
AJA J Gerard Jansen
A J Gerard Jansen
Lupus anticoagulans (LACs) and aPLs, both further summarized as aPL, are frequently assessed in routine daily clinical practice in diagnostic workups for suspected autoimmune diseases or to test for underlying risk factors in patients with thrombosis or obstetric complications. The aim of this study was to determine the prevalence of aPL positivity in patients with an indication for aPL testing in routine clinical practice. In this retrospective single-centre study, indication for aPL testing, aPL test results and clinical data were collected for patients tested between June 2015 and April 2018. During the study period, 16 847 single aPL tests were performed in 2139 patients. In 212 patients one or more positive aPL test was found, confirmed in 43.9% with a second positive test. Indications for aPL testing were diagnostic workup/follow-up of autoimmune diseases (33.6%), thrombosis (21.4%) and obstetric complications (28%). Seventy-four patients (3.5% of all patients) fulfilled the criteria of APS, of whom 51% were newly diagnosed. Second positive aPL titres and titres of APS patients were significantly higher compared with positive aPL titres at the first measurement (P < 0.05). Patients with indications of arterial thrombosis and diagnostic workup/follow-up of autoimmune diseases had significantly higher levels of aCL IgG and anti-β2 glycoprotein I (β2GPI) IgG compared with patients with other indications. The prevalence of one or more positive aPL test was 9.9% and APS was diagnosed in 3.5% of the patients. Patients with arterial thrombosis had significantly higher anti-β2GPI IgG and aCL IgG, which should be confirmed in future studies.